Literature DB >> 32077319

The prevalence and prognostic significance of interatrial block in the general population.

Tiia Istolahti1,2, Antti Eranti3, Heini Huhtala4, Leo-Pekka Lyytikäinen1,5,6, Mika Kähönen1,7, Terho Lehtimäki1,6, Markku Eskola1,5, Ismo Anttila8, Antti Jula9, Antoni Bayés de Luna10, Kjell Nikus1,5, Jussi Hernesniemi1,5.   

Abstract

Introduction: Partial and advanced interatrial block (IAB) in the electrocardiographic (ECG) represents inter-atrial conduction delay. IAB is associated with atrial fibrillation (AF) and stroke in the general population.Material and methods: A representative sample of Finnish subjects (n = 6354) aged over 30 years (mean: 52.2 years, standard deviation: 14.6) underwent a health examination including a 12-lead ECG. Five different IAB groups based on automatic measurements were compared to normal P waves using multivariate-adjusted Cox proportional hazard model. Follow-up lasted up to 15 years.
Results: The prevalence of advanced and partial IAB was 1.0% and 9.7%, respectively. In the multivariate model, both advanced (hazard ratio (HR): 1.63 (95% confidence interval (CI): 1.00-2.65)) and partial IAB (HR: 1.39 (1.09-1.77)) were associated with increased risk of AF. Advanced IAB was associated with increased risk of stroke or transient ischaemic attack (TIA) independently of associated AF (HR: 2.22 (1.20-4.13)). Partial IAB was also associated with increased risk of being diagnosed with coronary heart disease (HR: 1.26 (1.01-1.58)).Discussion: IAB is a rather frequent finding in the general population. IAB is a risk factor for AF and is associated with an increased risk of stroke or TIA independently of associated AF.Key messagesBoth partial and advanced interatrial block are associated with increased risk of atrial fibrillation in the general population.Advanced interatrial block is an independent risk factor for stroke and transient ischaemic attack.The clinical significance of interatrial block is dependent on the subtype classification.

Entities:  

Keywords:  ECG; Interatrial block; atrial fibrillation; mortality; population study

Year:  2020        PMID: 32077319      PMCID: PMC7877939          DOI: 10.1080/07853890.2020.1731759

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  25 in total

1.  Progression of partial to advanced interatrial block.

Authors:  Vignendra Ariyarajah; David H Spodick
Journal:  J Electrocardiol       Date:  2005-11-10       Impact factor: 1.438

Review 2.  Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences.

Authors:  Benjamin J Hirsh; Robert S Copeland-Halperin; Jonathan L Halperin
Journal:  J Am Coll Cardiol       Date:  2015-05-26       Impact factor: 24.094

3.  Incidence rates, correlates, and prognosis of electrocardiographic P-wave abnormalities - a nationwide population-based study.

Authors:  Arttu O Lehtonen; Ville L Langén; Pauli J Puukka; Mika Kähönen; Markku S Nieminen; Antti M Jula; Teemu J Niiranen
Journal:  J Electrocardiol       Date:  2017-07-12       Impact factor: 1.438

4.  Analysis of the Association Between Electrocardiographic P-wave Characteristics and Atrial Fibrillation in the REGICOR Study.

Authors:  Albert Massó-van Roessel; Luis Alberto Escobar-Robledo; Irene R Dégano; María Grau; Joan Sala; Rafel Ramos; Jaume Marrugat; Antoni Bayés de Luna; Roberto Elosua
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2017-03-18

5.  Potential clinical correlates and risk factors for interatrial block.

Authors:  Vignendra Ariyarajah; Sirin Apiyasawat; Ranjani Moorthi; David H Spodick
Journal:  Cardiology       Date:  2006-02-22       Impact factor: 1.869

6.  Interatrial blocks. A separate entity from left atrial enlargement: a consensus report.

Authors:  Antonio Bayés de Luna; Pyotr Platonov; Francisco G Cosio; Iwona Cygankiewicz; Carlos Pastore; Rafa Baranowski; Antoni Bayés-Genis; Josep Guindo; Xavier Viñolas; Javier Garcia-Niebla; Raimundo Barbosa; Shlomo Stern; David Spodick
Journal:  J Electrocardiol       Date:  2012-09       Impact factor: 1.438

7.  Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study.

Authors:  Arshad Jahangir; Victor Lee; Paul A Friedman; Jane M Trusty; David O Hodge; Stephen L Kopecky; Douglas L Packer; Stephen C Hammill; Win-Kuang Shen; Bernard J Gersh
Journal:  Circulation       Date:  2007-06-04       Impact factor: 29.690

8.  Risk Prediction of Atrial Fibrillation Based on Electrocardiographic Interatrial Block.

Authors:  Morten W Skov; Jonas Ghouse; Jørgen T Kühl; Pyotr G Platonov; Claus Graff; Andreas Fuchs; Peter V Rasmussen; Adrian Pietersen; Børge G Nordestgaard; Christian Torp-Pedersen; Steen M Hansen; Morten S Olesen; Stig Haunsø; Lars Køber; Thomas A Gerds; Klaus F Kofoed; Jesper H Svendsen; Anders G Holst; Jonas B Nielsen
Journal:  J Am Heart Assoc       Date:  2018-05-30       Impact factor: 5.501

Review 9.  Bayés' syndrome: Time to consider early anticoagulation?

Authors:  Adrian Baranchuk; Bryce Alexander; Goksel Cinier; Manuel Martinez-Selles; Ahmet Ilker Tekkesin; Roberto Elousa; Antoni Bayes De Luna
Journal:  North Clin Istanb       Date:  2018-05-23

10.  Advanced interatrial block and ischemic stroke: The Atherosclerosis Risk in Communities Study.

Authors:  Wesley T O'Neal; Hooman Kamel; Zhu-Ming Zhang; Lin Y Chen; Alvaro Alonso; Elsayed Z Soliman
Journal:  Neurology       Date:  2016-06-24       Impact factor: 9.910

View more
  2 in total

1.  Advanced interatrial block predicts ineffective cardioversion of atrial fibrillation: a FinCV2 cohort study.

Authors:  Arto Relander; Tapio Hellman; Tuija Vasankari; Ilpo Nuotio; Juhani K E Airaksinen; Tuomas Kiviniemi
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

2.  Advanced Interatrial Block Predicts Recurrence of Atrial Fibrillation and Ischemic Stroke in Elderly Patients With Hypertension.

Authors:  Haijun Wang; Lili Cai; Yan Guo; Li Shuai; Yang Shi; Quanjin Si
Journal:  Front Physiol       Date:  2022-06-16       Impact factor: 4.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.